Mark Rothera - 30 Nov 2023 Form 4 Insider Report for Viracta Therapeutics, Inc. (VIRX)

Reporting relationship: President and CEO, Director
Issuer ticker: VIRX
Reported as of: 30 Nov 2023
Net transaction value: +$49,362
SEC form: 4
Accepted by SEC: 04 Dec 2023, 16:54:41 UTC
Prior SEC filing: 17 Mar 2023
Next SEC filing: 13 Mar 2024
Source filing: View source filing
Reporting owner signature: Daniel Chevallard, as Attorney-in-Fact

Key filing fact

Mark Rothera filed Form 4 for Viracta Therapeutics, Inc. (VIRX) on 04 Dec 2023.

Key facts

This page summarizes Mark Rothera's Form 4 filing for Viracta Therapeutics, Inc. (VIRX).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 04 Dec 2023, 16:54.

Change

Previous filing in this sequence was filed on 17 Mar 2023.
Current net transaction value: +$49,362.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VIRX transaction

Common Stock

Purchase

Transaction value: $25,734
Shares: +52,094
Change %
Price: $0.4940
Shares after: 52,094
Date: 30 Nov 2023
Ownership: Direct
Footnotes: F1

VIRX transaction

Common Stock

Purchase

Transaction value: $23,627
Shares: +47,906
Change %: +92%
Price: $0.4932
Shares after: 100,000
Date: 01 Dec 2023
Ownership: Direct
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents the weighted average share price of an aggregate total of 52,094 shares purchased in the price range of $0.48 to $0.51 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

Footnote F2

Represents the weighted average share price of an aggregate total of 47,906 shares purchased in the price range of $0.4750 to $0.5130 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.